Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C

World Journal of Hepatology

Volumn 6, Issue 7, 2014, Pages 520-526

  Rao, P N ^a   Koshy, Abraham ^b   Philip, Jacob ^c   Premaletha, Narayanan ^d   Varghese, Joy ^e   Narayanasamy, Krishnasamy ^e   Mohindra, Samir ^f   Pai, Nitin Vikas ^e   Agarwal, Manoj Kumar ^g   Konar, Ashoknanda ^h   Vora, Hasmukh B ⁱ  

^a ASIAN INSTITUTE OF GASTROENTEROLOGY   (India)

^b Lakeshore Hospital and Research Centre   (India)

^c Department of General Surgery   (India)

^d GOVERNMENT MEDICAL COLLEGE   (India)

^e Global Hospitals and Health City ^*  (India)

^f SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^g Belle Vue Clinic   (India)

^h PEERLESS HOSPITAL   (India)

ⁱ Department of Gastroenterology Alka Hospital   (India)

Author keywords

Genotype; Hepatitis C virus; Peginterferon alfa 2b; Ribavirin; Treatment

Indexed keywords

EID: 84905971915     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i7.520     Document Type: Article

References (29)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47 [PMID: 10847128 DOI: 10.1046/j. 1365-2893.1999.6120139.x]
2. WHO. Hepatitis C. WHO Fact sheet No 164. Available from: URL: http://www.who.int/mediacentre/factsheets/fs164/en/
3. Mukhopadhyaya A. Hepatitis C in India. J Biosci 2008; 33: 465-473 [PMID: 19208972 DOI: 10.4103/1947-2714.103325]
4. Ghany MG, Strader DB, Thomas DL, SeeffLB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]
5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
6. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409-435 [DOI: 10.1007/s12072-012-9342-y]
7. Ghany MG, Nelson DR, Strader DB, Thomas DL, SeeffLB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444 [PMID: 21898493 DOI: 10.1002/hep.24641]
8. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-1233 [PMID: 10210705 DOI: 10.1056/NEJM199904223401602]
9. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31: 1014-1018 [PMID: 10733560 DOI: 10/S0270913900298170]
10. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, del Valle Onorato M, Rodés J, Ordinas A. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21: 639-644 [PMID: 7533121]
11. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010; 4: 548-561 [PMID: 21063477 DOI: 10.1007/s12072-010-9193-3]
12. Hissar SS, Goyal A, Kumar M, Pandey C, Suneetha PV, Sood A, Midha V, Sakhuja P, Malhotra V, Sarin SK. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 2006; 78: 452-458 [PMID: 16482560 DOI: 10.1002/jmv.20561]
13. Narahari S, Juwle A, Basak S, Saranath D. Prevalence and geographic distribution of Hepatitis C Virus genotypes in Indian patient cohort. Infect Genet Evol 2009; 9: 643-645 [PMID: 19460332 DOI: 10.1016/j.meegid.2009.04.001]
14. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965 [PMID: 11583749 DOI: 10.1016/S0140-6736(01)06102-5]
15. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, Vinelli F, Scotto G, Montalto G, Romano M, Cristofaro G, Mottola L, Spirito F, Andriulli A. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008; 47: 43-50 [PMID: 18069698 DOI: 10.1002/hep.22061]
16. Kainuma M, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Shimono J, Shimoda S, Hayashi J. Pegylated interferon a-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16: 4400-4409 [PMID: 20845506 DOI: 10.3748/wjg.v16.i35.4400]
17. Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol 2011; 55: 554-563 [PMID: 21237227 DOI: 10.1016/j.jhep.2010.12.024]
18. Kanda T, Imazeki F, Azemoto R, Yonemitsu Y, Mikami S, Kita K, Takashi M, Sunaga M, Wu S, Nakamoto S, Tawada A, Arai M, Kato K, Yoshida Y, Koma Y, Fujiwara K, Fukai K, Suzuki N, Yokosuka O. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci 2011; 56: 3335-3342 [PMID: 21604145 DOI: 10.1007/s10620-011-1750-7]
19. Al-Ali J, Siddique I, Varghese R, Hasan F. Pegylated interferon- alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT. Ann Hepatol 2012; 11: 186-193 [PMID: 22345335]
20. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004; 20: 931-938 [PMID: 15521839 DOI: 10.1111/j.1365-2036.2004.02208.x]
21. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355 [PMID: 14996676]
22. Poordad F, Landaverde C. Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients. Therap Adv Gastroenterol 2009; 2: 91-97 [PMID: 21180537 DOI: 10.1177/1756283X08101217]
23. Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, Moustafa A, Hakem SA, Ibrahiem A, Moniem M, Mansour H, Abdelaziz M. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 2007; 46: 1732-1740 [PMID: 17943989]
24. Poordad FF. Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C. Aliment Pharmacol Ther 2010; 31: 1251-1267 [PMID: 20236258 DOI: 10.1111/j.1365-2036.2010.04300.x]
25. Gralewicz S, Eckersdorf B, Golebiewski H. Hippocampal rhythmic slow activity (RSA) in the cat after intraseptal injections of muscarinic cholinolytics. Acta Neurobiol Exp (Wars) 1992; 52: 211-221 [PMID: 1293959 DOI: 10.1053/jhep. 2003.50364]
26. Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo PY, Santoro J, Becker S, Wakil AE, Pound D, Godofsky E, Strauss R, Bernstein D, Flamm S, Pauly MP, Mukhopadhyay P, Griffel LH, Brass CA. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-981 [PMID: 17894303 DOI: 10.1002/hep.21932]
27. Sood A, Midha V, Hissar S, Kumar M, Suneetha PV, Bansal M, Sood N, Sakhuja P, Sarin SK. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. J Gastroenterol Hepatol 2008; 23: 203-207 [PMID: 17645472 DOI: 10.1111/j.1440-1746.2007.05057.x]
28. Ray G, Pal S, Nayyar I, Dey S. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India. Trop Gastroenterol 2007; 28: 109-112 [PMID: 18383998]
29. WHO. Guidelines for the screening, care and treatment of persons with hepatitis c infection. Available from: URL: http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_ eng.pdf?ua=1